Mar 22, 2022 / 12:30PM GMT
Operator
Good morning, everyone, and welcome to the argenx Phase III ADAPT-SC Trial Top Line Results Conference Call. (Operator Instructions). To follow the presentation, we ask that you navigate the slides as directed by argenx management. There will be a question-and-answer session to follow.
I would now like to introduce Beth DelGiacco, Vice President of Corporate Communications and Investor Relations at argenx.
Beth DelGiacco - argenx SE - VP of IR
Thank you, and good morning to everyone on the call. Earlier today, we issued a press release summarizing our positive Top Line Phase III ADAPT-Subcu Trial Results. The press release and the presentation for today's webcast can be found on our website.
On the call today are Tim Van Hauwermeiren, our Chief Executive Officer; and Keith Woods, our Chief Operating Officer. Wim Parys, our Chief Medical Officer, will also be available for the Q&A session following prepared remarks.
Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call
argenx SE Topline Phase 3 Data From ADAPT-SC Study Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers